絞り込み

18390

広告

アカウミガメ 人工繁殖で3世代目が誕生 和歌山 串本町 (NHK)

アカウミガメの繁殖に取り組んでいる和歌山県串本町の水族館で、人が飼育する環境で3世代目の繁殖に成功しました。水族館によりますと世界で初めてだということです。 串...

  1. くらしナビ・社会保障:新型コロナ 保育園...
  2. 医療の本音:和を尊び脱コロナへ=松本尚(...
  3. 新型コロナ 中国新車販売、回復鮮明 日米...
  4. いきものと生きる:宮古島のヒラタクワガタ...

ニュース一覧

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters.

著者 Abe I , Ochi K , Takashi Y , Yamao Y , Ohishi H , Fujii H , Minezaki M , Sugimoto K , Kudo T , Abe M , Ohnishi Y , Mukoubara S , Kobayashi K
Medicine (Baltimore).2019 Nov ; 98(47):e18067.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (38view , 0users)
Osteoporosis is a complication of type 2 diabetes mellitus (T2DM). Blockade of receptor activator of nuclear factor kappa-B ligand (RANKL) improves osteoporosis, but might also improve glucose tolerance through reduction of hepatic insulin resistance. However, the effect of denosumab (a human monoclonal antibody of RANKL) upon glycemic and metabolic parameters is controversial. We revealed the effect of denosumab upon glycemic and metabolic parameters for 52 weeks. We evaluated 20 individuals diagnosed with both osteoporosis (male and female: postmenopausal) and T2DM. We measured glycemic and metabolic parameters before and 26/52 weeks after administration of denosumab (60 mg per 26 weeks) without changing any other medication each patient was taking. All patients completed the study without complications and the T-score (lumbar spine and femoral neck) improved significantly from baseline to 52 weeks after denosumab administration (P < .001, .001, respectively). None of the glycemic parameters changed significantly from baseline to 26 weeks after denosumab administration, but levels of glycated hemoglobin and homeostasis model assessment of insulin resistance improved significantly from baseline to 52 weeks after administration (P = .019, .008, respectively). The levels of liver enzymes did not change significantly from baseline to 26 weeks after denosumab administration, but levels of aspartate transaminase and alanine aminotransferase improved significantly from baseline to 52 weeks after administration (P = .014, .004, respectively). None of the markers of lipid metabolism and body mass index changed significantly from baseline to 26/52 weeks after denosumab administration. These data demonstrated that denosumab is useful for T2DM patients with osteoporosis for glycemic control via improvement of insulin resistance. Also, the effect of denosumab might be due to improvement of hepatic function.
PMID: 31764838 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード